Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70

Ashvini Keshavan, Josef Pannee, Thomas K. Karikari, Juan Lantero Rodriguez, Nicholas J. Ashton, Jennifer M. Nicholas, David M. Cash, William Coath, Christopher A. Lane, Thomas D. Parker, Kirsty Lu, Sarah M. Buchanan, Sarah E. Keuss, Sarah Naomi James, Heidi Murray-Smith, Andrew Wong, Anna Barnes, John C. Dickson, Amanda Heslegrave, Erik PorteliusMarcus Richards, Nick C. Fox, Henrik Zetterberg, Kaj Blennow, Jonathan M. Schott*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Alzheimer's disease has a preclinical stage when cerebral amyloid-β deposition occurs before symptoms emerge, and when amyloid-β-Targeted therapies may have maximum benefits. Existing amyloid-β status measurement techniques, including amyloid PET and CSF testing, are difficult to deploy at scale, so blood biomarkers are increasingly considered for screening. We compared three different blood-based techniques-liquid chromatography-mass spectrometry measures of plasma amyloid-β, and single molecule array (Simoa) measures of plasma amyloid-β and phospho-Tau181-to detect cortical 18F-florbetapir amyloid PET positivity (defined as a standardized uptake value ratio of >0.61 between a predefined cortical region of interest and eroded subcortical white matter) in dementia-free members of Insight 46, a substudy of the population-based British 1946 birth cohort. We used logistic regression models with blood biomarkers as predictors of amyloid PET status, with or without age, sex and APOE ϵ4 carrier status as covariates. We generated receiver operating characteristics curves and quantified areas under the curves to compare the concordance of the different blood tests with amyloid PET. We determined blood test cut-off points using Youden's index, then estimated numbers needed to screen to obtain 100 amyloid PET-positive individuals. Of the 502 individuals assessed, 441 dementia-free individuals with complete data were included; 82 (18.6%) were amyloid PET-positive. The area under the curve for amyloid PET status using a base model comprising age, sex and APOE ϵ4 carrier status was 0.695 (95% confidence interval: 0.628-0.762). The two best-performing Simoa plasma biomarkers were amyloid-β42/40 (0.620; 0.548-0.691) and phospho-Tau181 (0.707; 0.646-0.768), but neither outperformed the base model. Mass spectrometry plasma measures performed significantly better than any other measure (amyloid-β1-42/1-40: 0.817; 0.770-0.864 and amyloid-β composite: 0.820; 0.775-0.866). At a cut-off point of 0.095, mass spectrometry measures of amyloid-β1-42/1-40 detected amyloid PET positivity with 86.6% sensitivity and 71.9% specificity. Without screening, to obtain 100 PET-positive individuals from a population with similar amyloid PET positivity prevalence to Insight 46, 543 PET scans would need to be performed. Screening using age, sex and APOE ϵ4 status would require 940 individuals, of whom 266 would proceed to scan. Using mass spectrometry amyloid-β1-42/1-40 alone would reduce these numbers to 623 individuals and 243 individuals, respectively. Across a theoretical range of amyloid PET positivity prevalence of 10-50%, mass spectrometry measures of amyloid-β1-42/1-40 would consistently reduce the numbers proceeding to scans, with greater cost savings demonstrated at lower prevalence.

Original languageEnglish
Pages (from-to)434-449
Number of pages16
JournalBrain
Volume144
Issue number2
DOIs
Publication statusPublished - 1 Feb 2021

Keywords

  • Alzheimer's disease
  • amyloid imaging
  • beta-Amyloid
  • dementia
  • epidemiology
  • tau

Cite this